FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132898413> ?p ?o ?g. }

• W3132898413 endingPage "1022" @default.
• W3132898413 startingPage "1009" @default.
• W3132898413 abstract "The majority of patients with newly diagnosed metastatic prostate cancer (PC) initially respond to androgen deprivation therapy (ADT) and are classified as metastatic castration-sensitive PC (mCSPC). Following months to years of ADT, the disease tends to become resistant to ADT. Recent randomized phase-III trials demonstrated a survival benefit with the addition of upfront docetaxel to ADT in mCSPC. Following its implementation in routine care, this combined treatment strategy requires more detailed evaluation in a real-world setting.To assess the real-world outcome and safety of upfront docetaxel treatment in mCSPC.A multicenter retrospective cohort study in the Southeast Health Care Region of Sweden was performed. This region includes approximately 1.1 million citizens and the oncology departments of Linköping, Jönköping, and Kalmar. All patients given upfront docetaxel for mCSPC from July 2015 until December 2017 were included. The primary endpoint was progression-free survival (PFS) at 12 mo, and the secondary endpoints were PFS at 24 mo, overall survival (OS), treatment intensity, adverse events, and unplanned hospitalizations. Exploratory analyses on potential prognostic parameters were performed.Ninety-four patients were eligible and formed the study cohort. PFS at 12 and 24 mo was 75% (95%CI: 66-84) and 58% (46-70), respectively. OS at 12 and 24 mo was 93% (87-99) and 86% (76-96). A total of 91% of patients (n = 86) were given docetaxel according to the standard protocol of 75 mg/m2 every 3 wk (6 cycles), while 9% (n = 8) received a modified protocol of 50 mg/m2 every 2 wk (9 cycles). The average overall dose intensity for those commencing standard treatment was 91%. Univariate Cox regression analyses show that baseline PSA > 180 vs < 180 and the presence of distant metastases vs locoregional lymph node metastases were only negative prognostic factors (HR 2.86, 95%CI: 1.39-5.87, P = 0.0041 and 3.36, 95%CI: 1.03-10.96, P = 0.045). Following multivariate analysis, statistical significance remained for PSA (2.51, 95%CI: 1.21-5.19, P = 0.013) but not for metastatic status (2.60, 95%CI: 0.78-8.65, P = 0.12). Febrile neutropenia was recorded in 21% (n = 20) of patients, and 26% (n = 24) had at least one episode of unplanned hospitalization under and up to 30 d after the treatment course.Results from this study support the implementation of upfront docetaxel plus ADT as part of the standard of care treatment strategy in mCSPC." @default.
• W3132898413 created "2021-03-01" @default.
• W3132898413 creator A5013006194 @default.
• W3132898413 creator A5032374166 @default.
• W3132898413 creator A5037497573 @default.
• W3132898413 creator A5037660153 @default.
• W3132898413 creator A5064767353 @default.
• W3132898413 creator A5066614167 @default.
• W3132898413 creator A5072199873 @default.
• W3132898413 creator A5076712827 @default.
• W3132898413 date "2021-11-24" @default.
• W3132898413 modified "2023-10-16" @default.
• W3132898413 title "Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer" @default.
• W3132898413 cites W1987456698 @default.
• W3132898413 cites W1989683537 @default.
• W3132898413 cites W2120292596 @default.
• W3132898413 cites W2136112016 @default.
• W3132898413 cites W2141454098 @default.
• W3132898413 cites W2142466432 @default.
• W3132898413 cites W2150865892 @default.
• W3132898413 cites W2155839539 @default.
• W3132898413 cites W2168242827 @default.
• W3132898413 cites W2214621962 @default.
• W3132898413 cites W2240099744 @default.
• W3132898413 cites W2460412619 @default.
• W3132898413 cites W2599194052 @default.
• W3132898413 cites W2617245288 @default.
• W3132898413 cites W2799931007 @default.
• W3132898413 cites W2889646458 @default.
• W3132898413 cites W2899118664 @default.
• W3132898413 cites W2964934281 @default.
• W3132898413 cites W3023530700 @default.
• W3132898413 doi "https://doi.org/10.5306/wjco.v12.i11.1009" @default.
• W3132898413 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34909396" @default.
• W3132898413 hasPublicationYear "2021" @default.
• W3132898413 type Work @default.
• W3132898413 sameAs 3132898413 @default.
• W3132898413 citedByCount "4" @default.
• W3132898413 countsByYear W31328984132022 @default.
• W3132898413 countsByYear W31328984132023 @default.
• W3132898413 crossrefType "journal-article" @default.
• W3132898413 hasAuthorship W3132898413A5013006194 @default.
• W3132898413 hasAuthorship W3132898413A5032374166 @default.
• W3132898413 hasAuthorship W3132898413A5037497573 @default.
• W3132898413 hasAuthorship W3132898413A5037660153 @default.
• W3132898413 hasAuthorship W3132898413A5064767353 @default.
• W3132898413 hasAuthorship W3132898413A5066614167 @default.
• W3132898413 hasAuthorship W3132898413A5072199873 @default.
• W3132898413 hasAuthorship W3132898413A5076712827 @default.
• W3132898413 hasBestOaLocation W31328984131 @default.
• W3132898413 hasConcept C121608353 @default.
• W3132898413 hasConcept C126322002 @default.
• W3132898413 hasConcept C143998085 @default.
• W3132898413 hasConcept C197934379 @default.
• W3132898413 hasConcept C203092338 @default.
• W3132898413 hasConcept C2777899217 @default.
• W3132898413 hasConcept C2780192828 @default.
• W3132898413 hasConcept C2781190966 @default.
• W3132898413 hasConcept C535046627 @default.
• W3132898413 hasConcept C71924100 @default.
• W3132898413 hasConcept C72563966 @default.
• W3132898413 hasConceptScore W3132898413C121608353 @default.
• W3132898413 hasConceptScore W3132898413C126322002 @default.
• W3132898413 hasConceptScore W3132898413C143998085 @default.
• W3132898413 hasConceptScore W3132898413C197934379 @default.
• W3132898413 hasConceptScore W3132898413C203092338 @default.
• W3132898413 hasConceptScore W3132898413C2777899217 @default.
• W3132898413 hasConceptScore W3132898413C2780192828 @default.
• W3132898413 hasConceptScore W3132898413C2781190966 @default.
• W3132898413 hasConceptScore W3132898413C535046627 @default.
• W3132898413 hasConceptScore W3132898413C71924100 @default.
• W3132898413 hasConceptScore W3132898413C72563966 @default.
• W3132898413 hasIssue "11" @default.
• W3132898413 hasLocation W31328984131 @default.
• W3132898413 hasLocation W31328984132 @default.
• W3132898413 hasLocation W31328984133 @default.
• W3132898413 hasLocation W31328984134 @default.
• W3132898413 hasOpenAccess W3132898413 @default.
• W3132898413 hasPrimaryLocation W31328984131 @default.
• W3132898413 hasRelatedWork W2060708716 @default.
• W3132898413 hasRelatedWork W2403920140 @default.
• W3132898413 hasRelatedWork W2588988563 @default.
• W3132898413 hasRelatedWork W2770702948 @default.
• W3132898413 hasRelatedWork W2776356588 @default.
• W3132898413 hasRelatedWork W2890184401 @default.
• W3132898413 hasRelatedWork W3089313947 @default.
• W3132898413 hasRelatedWork W3132581442 @default.
• W3132898413 hasRelatedWork W785005902 @default.
• W3132898413 hasRelatedWork W2563135651 @default.
• W3132898413 hasVolume "12" @default.
• W3132898413 isParatext "false" @default.
• W3132898413 isRetracted "false" @default.
• W3132898413 magId "3132898413" @default.
• W3132898413 workType "article" @default.